CRISPR Therapeutics AG — Director's Dealing 2020

Mar 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-03-10

Reporting Person: KASINGER JAMES R. (General Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-10	Stock Option (Right to Buy)	$44.67	A	35000	Acquired	2030-03-10	Common Shares (35000)	Direct
2020-03-10	Restricted Stock Units	$	A	8500	Acquired		Common Shares (8500)	Direct

Footnotes

F1: This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.